ConductScience.org, home

Paper786455

Mitomycin C: a review.

Crooke ST and 1 other. Cancer Treat Rev, 1976. Cited by 486 papers, by iCite.

Cite this record

ConductScience Library. Mitomycin C: a review. Papers, record 786455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/786455

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mitomycin C: a review.
PubMed
Journal
Cancer Treat Rev
PubMed
Year
1976
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
486
iCite
Relative citation ratio, by iCite
17.3
iCite
Revised in PubMed
2021-12-03
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Crooke STS T
2Bradner WTW T

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MitomycinsMajor topic
NeoplasmsMajor topic
Animals
DNA
Drug Administration Schedule
Drug Resistance, Microbial
Humans
Immunosuppression Therapy

Source PubMed

Download CSV of topics

Cited by93

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 486 citations.

PMIDTitleJournalYearIn PapersSource
41938163Sulfone-quinone derivatives: a review on their synthetic methods, properties and applications.RSC Adv2026https://conductscience.org/library/papers/41938163PubMed
41514559Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers (Basel)2025https://conductscience.org/library/papers/41514559PubMed
41491222Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.Br J Cancer2026https://conductscience.org/library/papers/41491222PubMed
41228359Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.Cancers (Basel)2025https://conductscience.org/library/papers/41228359PubMed
41199376Mitomycin C-induced DNA double-strand breaks are enhanced by catalytical inactivation of DNA polymerase κ in mice.Genes Environ2025https://conductscience.org/library/papers/41199376PubMed
40855509The isoflavone genistein selectively stimulates major satellite repeat transcription in mouse heterochromatin.Epigenetics Chromatin2025https://conductscience.org/library/papers/40855509PubMed
40809697Gynecologic postoperative anti-adhesion barriers: From biomaterials to barrier development.Biomater Biosyst2025https://conductscience.org/library/papers/40809697PubMed
40525407Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40525407PubMed
40351281Unveiling the research directions for pyrrolidine-based small molecules as versatile antidiabetic and anticancer agents.Future Med Chem2025https://conductscience.org/library/papers/40351281PubMed
40292320A high-throughput differential chemical genetic screen uncovers genotype-specific compounds altering plant growth.iScience2025https://conductscience.org/library/papers/40292320PubMed
39731542Discovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.J Am Chem Soc2025https://conductscience.org/library/papers/39731542PubMed
38279745Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation.Curr Top Med Chem2024https://conductscience.org/library/papers/38279745PubMed
38088585Secondary 3-Chloropiperidines: Powerful Alkylating Agents.ChemistryOpen2024https://conductscience.org/library/papers/38088585PubMed
38036976Screening of Natural Compounds for CYP11A1 Stimulation Against Cell Renal Cell Carcinoma.Biol Proced Online2023https://conductscience.org/library/papers/38036976PubMed
37996570Quinones from Cordia species from 1972 to 2023: isolation, structural diversity and pharmacological activities.Nat Prod Bioprospect2023https://conductscience.org/library/papers/37996570PubMed
37980694Three-membered ring formation catalyzed by α-ketoglutarate-dependent nonheme iron enzymes.J Nat Med2024https://conductscience.org/library/papers/37980694PubMed
37635891A Randomized Control Trial to Evaluate the Effect of Local Instillation of Mitomycin-C at the Porta after Kasai Portoenterostomy in Patients of Biliary Atresia.J Indian Assoc Pediatr Surg2023https://conductscience.org/library/papers/37635891PubMed
37397557Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes Dis2023https://conductscience.org/library/papers/37397557PubMed
35743251Use of Self-Assembled Colloidal Prodrug Nanoparticles for Controlled Drug Delivery of Anticancer, Antifibrotic and Antibacterial Mitomycin.Int J Mol Sci2022https://conductscience.org/library/papers/35743251PubMed
35704159Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.Ophthalmol Ther2022https://conductscience.org/library/papers/35704159PubMed

See all 93 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/786455

GET https://conductscience.org/api/papers/v1/786455/cited_by?page=2